This is a working overview of Visceral adiposity, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-21. Anything still debated is marked as such rather than presented as settled.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
== Medical uses == Ciclosporin is indicated to treat and prevent graft-versus-host disease in bone marrow transplantation and to prevent rejection of kidney, heart, and liver transplants. It is also approved in the US for treating of rheumatoid arthritis and psoriasis, persistent nummular keratitis following adenoviral keratoconjunctivitis, and as eye drops for treating dry eyes caused by Sjögren's disease and meibomian gland dysfunction. In addition to these indications, ciclosporin is also used in severe atopic dermatitis, It has been used in severe rheumatoid arthritis and related diseases. Ciclosporin has also been used in people with acute severe ulcerative colitis and hives that do not respond to treatment with steroids.
diphtheriae infection (Barcoo rot, diphtheric desert sore, septic sore, Veldt sore) Cutaneous group B streptococcal infection Cutaneous Pasteurella hemolytica infection Cutaneous Streptococcus iniae infection Dermatitis gangrenosa (gangrene of the skin) Ecthyma Ecthyma gangrenosum Ehrlichiosis ewingii infection Elephantiasis nostras Endemic typhus (murine typhus) Epidemic typhus (epidemic louse-borne typhus) Erysipelas (ignis sacer, Saint Anthony's fire) Erysipeloid of Rosenbach Erythema marginatum Erythrasma External otitis (otitis externa, swimmer's ear) Felon Flea-borne spotted fever Flinders Island spotted fever Flying squirrel typhus Folliculitis Fournier gangrene (Fournier gangrene of the penis or scrotum) Furunculosis (boil) Gas gangrene (clostridial myonecrosis, myonecrosis) Glanders (equinia, farcy, malleus) Gonococcemia (arthritis–dermatosis syndrome, disseminated gonococcal infection) Gonorrhea (clap) Gram-negative folliculitis Gram-negative toe web infection Granuloma inguinale (Donovanosis, granuloma genitoinguinale, granuloma inguinale tropicum, granuloma venereum, granuloma venereum genitoinguinale, lupoid form of groin ulceration, serpiginous ulceration of the groin, ulcerating granuloma of the pudendum, ulcerating sclerosing granuloma) Green nail syndrome Group JK Corynebacterium sepsis Haemophilus influenzae cellulitis Helicobacter cellulitis Hospital furunculosis Hot tub folliculitis (Pseudomonas aeruginosa folliculitis) Human granulocytotropic anaplasmosis Human monocytotropic ehrlichiosis Impetigo contagiosa Japanese spotted fever Leptospirosis (Fort Bragg fever, pretibial fever, Weil's disease) Listeriosis Ludwig's angina Lupoid sycosis Lyme disease (Afzelius' disease, Lyme borreliosis) Lymphogranuloma venereum (climatic bubo, Durand–Nicolas–Favre disease, lymphogranuloma inguinale, poradenitis inguinale, strumous bubo) Malakoplakia (malacoplakia) Mediterranean spotted fever (Boutonneuse fever) Melioidosis (Whitmore's disease) Meningococcemia Missouri Lyme disease Mycoplasma infection Necrotizing fasciitis (flesh-eating bacteria syndrome) Neonatal toxic shock-like exanthematous disease Nocardiosis Noma neonatorum North Asian tick typhus Ophthalmia neonatorum Oroya fever (Carrion's disease) Pasteurellosis Perianal cellulitis (perineal dermatitis, streptococcal perianal disease) Periapical abscess Pinta Pitted keratolysis (keratolysis plantare sulcatum, keratoma plantare sulcatum, ringed keratolysis) Plague Primary gonococcal dermatitis Pseudomonal pyoderma Pseudomonas hot-foot syndrome Pyogenic paronychia Pyomyositis Q fever Queensland tick typhus Rat-bite fever Recurrent toxin-mediated perineal erythema Rhinoscleroma Rickettsia aeschlimannii infection Rickettsialpox Rocky Mountain spotted fever Saber shin (anterior tibial bowing) Saddle nose Salmonellosis Scarlet fever Scrub typhus (Tsutsugamushi fever) Shigellosis Staphylococcal scalded skin syndrome (pemphigus neonatorum, Ritter's disease) Streptococcal intertrigo Superficial pustular folliculitis (impetigo of Bockhart, superficial folliculitis) Sycosis vulgaris (barber's itch, sycosis barbae) Syphilid Syphilis (lues) Tick-borne lymphadenopathy Toxic shock syndrome (streptococcal toxic shock syndrome, streptococcal toxic shock-like syndrome, toxic streptococcal syndrome) Trench fever (five-day fever, quintan fever, urban trench fever) Tropical ulcer (Aden ulcer, jungle rot, Malabar ulcer, tropical phagedena) Tularemia (deer fly fever, Ohara's disease, Pahvant Valley plague, rabbit fever) Verruga peruana Vibrio vulnificus infection Yaws (bouba, frambösie, parangi, pian)
== Pathophysiology == Penile erection is managed by two mechanisms: the reflex erection, which is achieved by directly touching the penile shaft, and the psychogenic erection, which is achieved by erotic or emotional stimuli. The former involves the peripheral nerves and the lower parts of the spinal cord, whereas the latter involves the limbic system of the brain. In both cases, an intact neural system is required for a successful and complete erection. Stimulation of the penile shaft by the nervous system leads to the secretion of nitric oxide (NO), which causes the relaxation of the smooth muscles of the corpora cavernosa (the main erectile tissue of the penis), and subsequently penile erection. Additionally, adequate levels of testosterone (produced by the testes) and an intact pituitary gland are required for the development of a healthy erectile system. As can be understood from the mechanisms of a normal erection, impotence may develop due to hormonal deficiency, disorders of the neural system, lack of adequate penile blood supply or psychological problems.
doi:10.1016/j.cell.2007.02.029. PMID 17350564. S2CID 14249277. Zaneveld J, Hamady M, Sueoka N, Knight R (28 February 2009). "CodonExplorer: An Interactive Online Database for the Analysis of Codon Usage and Sequence Composition". Bioinformatics for DNA Sequence Analysis. Methods in Molecular Biology. Vol. 537. pp. 207–232. doi:10.1007/978-1-59745-251-9_10. ISBN 978-1-58829-910-9. PMC 2953947. PMID 19378146.
== Van Deemter equation == The van Deemter equation relates height equivalent to a theoretical plate (HETP) of a chromatographic column to the various flow and kinetic parameters which cause peak broadening, as follows:
Sources: en.wikipedia.org
=== Roman era === During the Roman era there was a settlement named Abona at the present Sea Mills; this was important enough to feature in the 3rd-century Antonine Itinerary which documents towns and distances in the Roman empire, and was connected to Bath by a road. Archaeological excavations at Abona have found a street pattern, shops, cemeteries and wharves, indicating that the town served as a port. Another settlement at what is now Inns Court, Filwood, had possibly developed from earlier Iron Age farmsteads. There were also isolated villas and small settlements throughout the area, notably Kings Weston Roman Villa and another at Brislington.
=== Receptor autoradiography === The use of radiolabeled ligands to determine the tissue distributions of receptors is termed either in vivo or in vitro receptor autoradiography if the ligand is administered into the circulation (with subsequent tissue removal and sectioning) or applied to the tissue sections, respectively. Once the receptor density is known, in vitro autoradiography can also be used to determine the anatomical distribution and affinity of a radiolabeled drug towards the receptor. For in vitro autoradiography, radioligand was directly applying on frozen tissue sections without administration to the subject. Thus it cannot follow the distribution, metabolism and degradation situation completely in the living body. But because target in the cryosections is widely exposed and can direct contact with radioligand, in vitro autoradiography is still a quick and easy method to screen drug candidates, PET and SPECT ligands. The ligands are generally labeled with 3H (tritium), 18F (fluorine-18), 11C (carbon-11) or 125I (radioiodine). Compare to in vitro, ex vivo autoradiography were performed after administration of radioligand in the body, which can decrease the artifacts and are closer to the inner environment. The distribution of RNA transcripts in tissue sections by the use of radiolabeled, complementary oligonucleotides or ribonucleic acids ("riboprobes") is called in situ hybridization histochemistry.
=== Twitch speed === Fibers can also be classified on their twitch capabilities, into fast and slow twitch. These traits largely, but not completely, overlap the classifications based on color, ATPase, or MHC (myosin heavy chain). Some authors define a fast twitch fiber as one in which the myosin can split ATP very quickly. These mainly include the ATPase type II and MHC type II fibers. However, fast twitch fibers also demonstrate a higher capability for electrochemical transmission of action potentials and a rapid level of calcium release and uptake by the sarcoplasmic reticulum. The fast twitch fibers rely on a well-developed, anaerobic, short term, glycolytic system for energy transfer and can contract and develop tension at 2–3 times the rate of slow twitch fibers. Fast twitch muscles are much better at generating short bursts of strength or speed than slow muscles, and so fatigue more quickly. The slow twitch fibers generate energy for ATP re-synthesis by means of a long term system of aerobic energy transfer. These mainly include the ATPase type I and MHC type I fibers. They tend to have a low activity level of ATPase, a slower speed of contraction with a less well developed glycolytic capacity. Fibers that become slow-twitch develop greater numbers of mitochondria and capillaries making them better for prolonged work.
== Medical devices == A variety of medical devices are in use or under consideration for treatment of depression including devices that offer electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and cranial electrotherapy stimulation. The use of such devices in the United States requires approval by the U.S. Food and Drug Administration (FDA) after field trials. In 2010 an FDA advisory panel considered the question of how such field trials should be managed. Factors considered were whether drugs had been effective, how many different drugs had been tried, and what tolerance for suicides should be in field trials.
Sources: en.wikipedia.org
Aortic stenosis Congenital heart disease Hypertensive heart disease Hypertrophic cardiomyopathy The common factor amongst all these diseases is that they all cause varying degrees of remodelling (myocardial fibrosis) of the ventricles.
{\displaystyle \mathrm {eGFR} =141\ \times \ \mathrm {\min(SCr/k,1)} ^{a}\ \times \ \mathrm {\max(SCr/k,1)} ^{-1.209}\ \times \ 0.993^{\text{Age}}\ \times {\text{[1.018 if Female]}}\ \times {\text{[1.159 if Black]}}\ }
== Personal life == In 2002, at the age of 19, she gave birth to her son, whom she had with the musician Thomas-John Mitchell. Marlowe is named after Christopher Marlowe. She gave birth to another boy in 2022, whose father is the illustrator Stéphane Manel.
CH3CH2Br + SC(NH2)2 → [CH3CH2SC(NH2)2]Br [CH3CH2SC(NH2)2]Br + NaOH → CH3CH2SH + OC(NH2)2 + NaBr The thiourea route works well with primary halides, especially activated ones. Secondary and tertiary thiols are less easily prepared. Secondary thiols can be prepared from the ketone via the corresponding dithioketals. A related two-step process involves alkylation of thiosulfate to give the thiosulfonate ("Bunte salt"), followed by hydrolysis. The method is illustrated by one synthesis of thioglycolic acid:
Because of its behavior as a prodrug and its pharmacokinetic differences, lisdexamfetamine has a longer duration of therapeutic effect than immediate-release dextroamphetamine and shows reduced misuse potential. CYP2D6, dopamine β-hydroxylase (DBH), flavin-containing monooxygenase 3 (FMO3), butyrate-CoA ligase (XM-ligase), and glycine N-acyltransferase (GLYAT) are the enzymes known to metabolize amphetamine or its metabolites in humans. Amphetamine has a variety of excreted metabolic products, including 4-hydroxyamphetamine, 4-hydroxynorephedrine, 4-hydroxyphenylacetone, N-hydroxyamphetamine, benzoic acid, hippuric acid, norephedrine, and phenylacetone. Among these metabolites, the active sympathomimetics are 4-hydroxyamphetamine, 4-hydroxynorephedrine, norephedrine, and N-hydroxyamphetamine. The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination. The known metabolic pathways, detectable metabolites, and metabolizing enzymes in humans include the following:
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.